. 2011 Dec 23;80(1):37–65. doi: 10.3797/scipharm.1111-15

Tab. 4.

Summary of anticancer screening data at dose-dependent assay

Comp.	N^a	log GI₅₀			log TGI			log LC₅₀

		N1^b	Range	MG_MID	N2^b	Range	MG_MID	N3^b	Range	MG_MID
3.14	57	−55	−6.07 to −5.01	−5.48	17	−5.53 to −4.02	−4.21	5	−5.46 to −4.04	−4.05
3.16	59	59	−6.29 to −5.31	−5.52	58	−5.44 to −4.64	−4.89	50	−5.11 to −4.07	−4.32
3.18	59	59	−6.29 to −5.31	−5.57	59	−5.54 to −4.55	−5.04	56	−5.24 to −4.01	−4.51

N – number of human tumor cell lines tested at the 2nd stage assay;

N1, N2, N3 – number of sensitive cell lines, against which the compound possessed considerable growth inhibition according to mentioned parameter (log GI50, log TGI and log LC50 ≤ 4.00).